Furthermore, GLP-1 receptor agonists upregulate the expression of adipokines (166) and promote M2 macrophage polarization (167), clinical studies have demonstrated that administering the GLP-1 analogue liraglutide to individuals with obesity results in favorable modifications in plasma lipid profiles and a reduction in apolipoprotein B levels, which could significantly lower the risk of CVDs (168–171). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.